Enanta Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is October - September.

Millions USD. Fiscal year is Oct - Sep.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Mar '25 Mar 31, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021	Sep '20 Sep 30, 2020	2015 - 2019
Operating Revenue	64.46	67.64	79.2	86.16	97.07	122.47	Upgrade
Revenue	64.46	67.64	79.2	86.16	97.07	122.47	Upgrade
Revenue Growth (YoY)	-11.55%	-14.61%	-8.07%	-11.24%	-20.74%	-40.31%	Upgrade
Gross Profit	64.46	67.64	79.2	86.16	97.07	122.47	Upgrade
Selling, General & Admin	51.33	57.85	52.89	45.48	32.54	27.36	Upgrade
Research & Development	115.24	131.48	163.52	164.52	174.11	136.76	Upgrade
Operating Expenses	166.57	189.33	216.41	210	206.65	164.11	Upgrade
Operating Income	-102.11	-121.69	-137.21	-123.84	-109.57	-41.64	Upgrade
Interest Expense	-8.61	-10.94	-5.15	-	-	-	Upgrade
Interest & Investment Income	10.62	13.63	8.5	2.74	2.02	6.47	Upgrade
Other Non Operating Income (Expenses)	0.07	0.07	-	0.08	-0.03	0.15	Upgrade
EBT Excluding Unusual Items	-100.03	-118.93	-133.85	-121.02	-107.58	-35.02	Upgrade
Gain (Loss) on Sale of Investments	1.14	1.14	2.86	-1.17	-	-	Upgrade
Pretax Income	-98.89	-117.79	-131	-122.19	-107.58	-35.02	Upgrade
Income Tax Expense	-2.48	-1.74	2.82	-0.43	-28.58	1.15	Upgrade
Net Income	-96.42	-116.05	-133.82	-121.76	-79	-36.17	Upgrade
Net Income to Common	-96.42	-116.05	-133.82	-121.76	-79	-36.17	Upgrade
Shares Outstanding (Basic)	21	21	21	21	20	20	Upgrade
Shares Outstanding (Diluted)	21	21	21	21	20	20	Upgrade
Shares Change (YoY)	0.70%	0.90%	1.78%	2.14%	1.16%	-4.90%	Upgrade
EPS (Basic)	-4.54	-5.48	-6.38	-5.91	-3.92	-1.81	Upgrade
EPS (Diluted)	-4.54	-5.48	-6.38	-5.91	-3.92	-1.81	Upgrade
Free Cash Flow	-	-96.71	-112.21	-86.91	-70.75	5.64	Upgrade
Free Cash Flow Per Share	-	-4.57	-5.35	-4.22	-3.51	0.28	Upgrade
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	Upgrade
Operating Margin	-158.40%	-179.92%	-173.23%	-143.74%	-112.88%	-34.00%	Upgrade
Profit Margin	-149.57%	-171.58%	-168.95%	-141.31%	-81.38%	-29.53%	Upgrade
Free Cash Flow Margin	-	-142.99%	-141.67%	-100.87%	-72.88%	4.61%	Upgrade
EBITDA	-99.26	-119.36	-134.84	-120.87	-106.24	-38	Upgrade
EBITDA Margin	-153.98%	-176.47%	-170.24%	-140.29%	-109.44%	-31.02%	Upgrade
D&A For EBITDA	2.85	2.34	2.37	2.97	3.33	3.64	Upgrade
EBIT	-102.11	-121.69	-137.21	-123.84	-109.57	-41.64	Upgrade
EBIT Margin	-158.40%	-179.92%	-173.23%	-143.74%	-112.88%	-34.00%	Upgrade
Revenue as Reported	67.64	67.64	79.2	86.16	97.07	-	Upgrade

Updated Feb 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q